Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
The last earnings update was 21 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Hemispherx Biopharma. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Hemispherx Biopharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
Hemispherx Biopharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
Hemispherx Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Hemispherx Biopharma's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Hemispherx Biopharma's finances.
The net worth of a company is the difference between its assets and liabilities.
Hemispherx Biopharma's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Hemispherx Biopharma's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Hemispherx Biopharma's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is not covered by short term assets, assets are 0.6x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Thomas K. Equels, Esq. M.S., J.D. has been the Chief Executive Officer of Hemispherx Biopharma, Inc. since February 25, 2016 and its President since August 13, 2015. Mr. Equels has been an Executive Vice Chairman at Hemispherx Biopharma, Inc. since 2008 and served as its Secretary since January April 2009. He serves as Litigation Counsel of Hemispherx Biopharma Inc., in a number of complex cases over ten years. He was owner of the Equels Law Firm. He served as the President and Managing Director of Equels Law Firm. He served as the Chief Financial Officer of Hemispherx Biopharma, Inc. since December 4, 2013 until February 19, 2015. He served as General Counsel of Hemispherx Biopharma, Inc. from January 1, 2010 to October 1, 2016. He served as Managing Director of Holtzman Equels P.A. For more than 25 years, he has represented national and state governments, banks, insurance companies, aviation companies, construction and development companies. Mr. Equels has extensive experience in international matters and served as counsel for the Republic of Panama, Chinese National Petroleum Corp. and worked extensively in Europe as well as in South America, Asia and Africa. He served as a Co-General Counsel of Hemispherx Biopharma, Inc from May 15, 2009 to January 1, 2010. He has been a Director at Hemispherx Biopharma, Inc. since November 28, 2008. He is a Member of the Florida Bar Association, the American Bar Association and the Academy of Florida Trial Lawyers. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate of Troy University and also obtained his Masters' Degree in Management from Troy University.
Thomas's compensation has increased whilst company is loss making.
Thomas's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Hemispherx Biopharma management team is about average.
Executive Vice Chairman
CFO & Chief Accounting Officer
Executive Director of Governmental Relations
Senior Vice President of Operations
Chief Scientific Officer & Medical Director
Ann Marie Coverly
Director of Administration & Human Resources and Investor Relations Manager
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company’s products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.